Provider notes

• NMUH:
  
  • Restricted for patients allergic to Warfain only.
  • Check MHRA Drug Safety Updates
• RFL:
  
  • Restricted for patients allergic to warfarin only
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

See NICE TA for eligibity criteria

Provider notes

• NMUH:
  
  • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • See links below
  • Check MHRA Drug Safety Update
  • A referral form must be completed by Authorised Teams/ Haematology team to initiate a DOAC
  • A GP notification form must be completed and sent to the GP for each patient newly started on a DOAC
  • A copy of the above forms (referral form and GP notification form) must be sent to the anticoagulant clinic
• RFL:
  
  • As per NICE guidance
  • Follow NCL DOAC prescribing guide
• RNOH:
  
  • No restriction stated
• UCLH:
• WH:
  
  • 2nd Choice DOAC - For Atrial Fibrillation / Stroke prevention.

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for (JFC January 2019):

• Multiple myeloma starting chemotherapy with thalidomide, lenalidomide or pomalidomide who would previously have received LMWH
• Newly diagnosed multiple myeloma with additional VTE risk factor

Dose is 2.5mg twice-daily.

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Approved for thromboprophylaxis for patients have thalidomide, lenalidomide, pomalidomide
• RNOH:
• Non-formulary
• UCLH:
• WH:
• As above

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

See NICE TA for eligibity criteria

Provider notes

• NMUH:
  
  • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • Restricted for thromboprophylaxis post elective total hip or knee replacement surgery and emergency hip fracture surgery, as per Trust guidelines.
  • See links below
  • Check MHRA Drug Safety Updates
  • A referral form must be completed by Authorised Teams/ Haematology team to initiate a DOAC
  • A GP notification form must be completed and faxed to the GP for each patient newly started on a DOAC
  • A copy of the above forms (referral form and GP notification form) must be sent to the anticoagulant clinic
• RFL:
  
  • As per NICE guidance
  • Follow NCL DOAC prescribing guide
• RNOH:
  
  • Follow NCL DOAC prescribing guide
• UCLH:
• WH:
  
  • Restricted for use as thromboprophylaxis after elective hip and knee surgery

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

See NICE TA for eligibity criteria

Provider notes

• NMUH:
  
  • Positive NICE TA - This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • A referral form must be completed by Authorised Teams/ Haematology team to initiate a DOAC
  • A GP notification form must be completed and sent to the GP for each patient newly started on a DOAC
  • A copy of the above forms (referral form and GP notification form) must be sent to the anticoagulant clinic
• RFL:
  
  • As per NICE guidance
  • Follow NCL DOAC prescribing guide
• RNOH:
  
  • No restriction stated
• UCLH:
• WH:
  
  • Not to be used for initiation of therapy.

Provider notes

• NMUH:
  
  • Non-formulary
• RFL:
  
  • Should only be used in patients who are allergic to warfarin.
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

See NICE TA for eligibility criteria

Provider notes

• NMUH:
  
  • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • For thromboprophylaxis for patients immobilised with lower limb plaster casts. Patient must have had a risk assessment for VTE and must receive the Trust Rivaroxaban Information for Patients leaflet (see links below).
  • Restricted to Haematologists only
  • Check MHRA Drug Safety Updates
  • A referral form must be completed by Authorised Teams/ Haematology team to initiate a DOAC
  • A GP notification form must be completed and sent to the GP for each patient newly started on a DOAC
  • A copy of the above forms (referral form and GP notification form) must be sent to the anticoagulant clinic
  • see links below
• RFL:
  
  • As per NICE guidance
  • Follow NCL DOAC prescribing guide
• RNOH:
  
  • No restriction stated
• UCLH:
• WH:
  
  • 1st Choice - For Atrial Fibrillation / Stroke prevention.

Provider notes

• NMUH:
  • See links below
  • Check MHRA drug safety update
• RFL:
  • No restriction stated
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • No restriction stated